181 related articles for article (PubMed ID: 28377889)
1. Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet.
García MI; de la Parra A; Arias C; Arredondo M; Cabello JF
Mol Genet Metab Rep; 2017 Jun; 11():12-16. PubMed ID: 28377889
[TBL] [Abstract][Full Text] [Related]
2. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls.
van Ginkel WG; Jahja R; Huijbregts SC; Daly A; MacDonald A; De Laet C; Cassiman D; Eyskens F; Körver-Keularts IM; Goyens PJ; McKiernan PJ; van Spronsen FJ
Orphanet J Rare Dis; 2016 Jun; 11(1):87. PubMed ID: 27356512
[TBL] [Abstract][Full Text] [Related]
4. Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening.
Hajji H; Imbard A; Spraul A; Taibi L; Barbier V; Habes D; Brassier A; Arnoux JB; Bouchereau J; Pichard S; Sissaoui S; Lacaille F; Girard M; Debray D; de Lonlay P; Schiff M
Mol Genet Metab Rep; 2022 Dec; 33():100933. PubMed ID: 36393896
[TBL] [Abstract][Full Text] [Related]
5. Treatment adherence in tyrosinemia type 1 patients.
González-Lamuño D; Sánchez-Pintos P; Andrade F; Couce ML; Aldámiz-Echevarría L
Orphanet J Rare Dis; 2021 Jun; 16(1):256. PubMed ID: 34082789
[TBL] [Abstract][Full Text] [Related]
6. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
7. A case report of two siblings with hypertyrosinemia type 1 presenting with hepatic disease with different onset time and severity.
Kawabata K; Kido J; Yoshida T; Matsumoto S; Nakamura K
Mol Genet Metab Rep; 2022 Sep; 32():100892. PubMed ID: 35800472
[TBL] [Abstract][Full Text] [Related]
8. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
9. Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1.
Dweikat I; Qawasmi N; Najeeb A; Radwan M
Metabol Open; 2021 Mar; 9():100083. PubMed ID: 33598652
[TBL] [Abstract][Full Text] [Related]
10. Case report: Maternal tyrosinemia type 1a under NTBC treatment with tyrosine- and phenylalanine restricted diet in Chile.
Medina MF; Arias C; Cabello JF; De la Parra A; Valiente A; Castro G; Fuenzalida K; Cornejo V
Am J Med Genet C Semin Med Genet; 2020 Dec; 184(4):1009-1013. PubMed ID: 33300677
[TBL] [Abstract][Full Text] [Related]
11. Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia.
Honar N; Shakibazad N; Serati Shirazi Z; Dehghani SM; Inaloo S
Iran J Child Neurol; 2017; 11(4):66-70. PubMed ID: 29201126
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic characteristics of two patients with tyrosinemia type 1 in Slovenia - A novel fumarylacetoacetate hydrolase (
Sikonja J; Brecelj J; Zerjav Tansek M; Repic Lampret B; Drole Torkar A; Klemencic S; Lipovec N; Stefanova Kralj V; Bertok S; Kovac J; Faganel Kotnik B; Tesarova M; Remec ZI; Debeljak M; Battelino T; Groselj U
Mol Genet Metab Rep; 2022 Mar; 30():100836. PubMed ID: 35242570
[TBL] [Abstract][Full Text] [Related]
13. Clinical Spectrum of Hereditary Tyrosinemia Type 1 in a Cohort of Pakistani Children.
Khan SA; Fakih M; Taufiq N; Ahmerin A; Bangash A; Iqbal Malik M
Clin Med Insights Pediatr; 2024; 18():11795565241236176. PubMed ID: 38456192
[TBL] [Abstract][Full Text] [Related]
14. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
15. Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1.
van Ginkel WG; van Vliet D; Burgerhof JGM; de Blaauw P; Rubio Gozalbo ME; Heiner-Fokkema MR; van Spronsen FJ
PLoS One; 2017; 12(9):e0185342. PubMed ID: 28949985
[TBL] [Abstract][Full Text] [Related]
16. Cost-Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I.
Simoncelli M; Samson J; Bussières JF; Lacroix J; Dorais M; Battista R; Perreault S
Can J Hosp Pharm; 2015; 68(3):210-7. PubMed ID: 26157182
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and intellectual functioning in patients with tyrosinemia type I.
Pohorecka M; Biernacka M; Jakubowska-Winecka A; Biernacki M; Kuśmierska K; Kowalik A; Sykut-Cegielska J
Pediatr Endocrinol Diabetes Metab; 2012; 18(3):96-100. PubMed ID: 23146787
[TBL] [Abstract][Full Text] [Related]
18. Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.
Thimm E; Herebian D; Assmann B; Klee D; Mayatepek E; Spiekerkoetter U
Mol Genet Metab; 2011 Feb; 102(2):122-5. PubMed ID: 21112803
[TBL] [Abstract][Full Text] [Related]
19. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
Couce ML; Dalmau J; del Toro M; Pintos-Morell G; Aldámiz-Echevarría L;
Pediatr Int; 2011 Dec; 53(6):985-9. PubMed ID: 21752152
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
